Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Dicot AB
  6. News
  7. Summary
    DICOT   SE0011178458

DICOT AB

(DICOT)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dicot Completes Study on Rats with Diabetes and Proven Erectile Dysfunction

10/14/2021 | 03:31am EST

Dicot has just completed a study on rats with diabetes and proven erectile dysfunction. The company's drug candidate demonstrated significantly improved erections compared to vehicle. In August 2021, Dicot released the results of its latest animal study on healthy rats, which concluded that the drug candidate LIB-01 has a longer effect on erection than other drugs on the market, and that the effect increases over time. The company is now publishing a new study, in collaboration with the French contract laboratory Pelvipharm, which includes rats with an underlying disease - diabetes. Due to the disease, these rats have a proven erectile dysfunction. In the established in vivo animal model, the study showed that Dicot's drug candidate significantly improved erection compared to vehicle at all measured parameters. The effect occurred after repeated dosing for three days and was measured 24 hours after the last administration. Up to 50-60% of all men with diabetes will experience erectile dysfunction and is believed to develop this ten to fifteen years earlier than men without diabetes.


ę S&P Capital IQ 2021
All news about DICOT AB
12/06Dicot's study results to be presented at leading scientific congress
AQ
12/02Dicot's potency drug candidate demonstrates efficiency and long duration even at a low ..
AQ
11/22Dicot's rights issue is registered - paid subscription units (BTU) are converted to sha..
AQ
11/18Summary of Interim Report January - September 2021, Dicot AB
AQ
11/18Dicot AB Reports Earnings Results for the Third Quarter and Nine Months Ended September..
CI
11/01Dicot's rights issue is subscribed with approx. 98 percent
AQ
10/20DICOT : Due to positive study results Dicot publishes a supplement prospectus
AQ
10/14DICOT : Study of animals with diabetes shows effect in Dicot's drug candidate
AQ
10/14Dicot Completes Study on Rats with Diabetes and Proven Erectile Dysfunction
CI
10/12DICOT : The subscription period for Dicot's rights issue begins today on October 12, 2021
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -17,5 M -1,93 M -1,93 M
Net cash 2020 20,3 M 2,23 M 2,23 M
P/E ratio 2020 -1,70x
Yield 2020 -
Capitalization - - -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 1
Free-Float -
Chart DICOT AB
Duration : Period :
Dicot AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
G÷ran Beijer Chief Executive Officer
Jessica Roxhed Chief Financial Officer
Eva Ulrika Sj÷kvist Saers Chairman
Jacob Westman Chief Technical Officer
Lena Carina S÷derstr÷m Independent Director